Research Specifications
- Molecule:
- LY3305677 — 39-amino-acid peptide
- Developer:
- Eli Lilly (licensed to Innovent in China)
- Class:
- Dual GLP-1 / Glucagon co-agonist
- Vial:
- 6mg lyophilized
- Purity:
- ≥98% HPLC verified
Mazdutide 6mg
GLP-1/Glucagon dual receptor agonist
CAS: 2259320-21-7
−16.8%
Weight loss (24wk)
Nahra 2023
Dual
GLP-1 + Glucagon
Receptor profile
Phase 3
Development stage
ClinicalTrials.gov
Receptor Targets
Active Phase 3 trials for obesity and T2DM
Developed by Eli Lilly (LY3305677). Greater China rights licensed to Innovent Biologics (IBI362). Under NMPA review in China as of 2024.
Also Known As
Reconstitution Protocol
BAC Water
1.5mL
Final Concentration
4 mg/mL
Per Dose
3 mg = 0.75 mL · 6 mg = 1.5 mL (full vial) · 9 mg = 2.25 mL
Phase 2 dosing was 9mg weekly; titrate from 1.5–3 mg
Research Stacks
| Compound | Why Researchers Stack It |
|---|---|
| BPC-157 | GI protection during GLP-1 titration |
Published References
- 1.Nahra R, Wang T, Gadde KM, et al.. Effects of Mazdutide, a novel dual GLP-1 and glucagon receptor agonist, in adults with obesity. Diabetes, Obesity and Metabolism (2023) PMID: 37148160
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| our verified supplier | >98% HPLC | $116.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Buy Peptides Compounds
Semaglutide 6mg
Survodutide 10mg
Tirzepatide 30mg
Tirzepatide 60mg
Mazdutide 6mg
$116.99